top of page

Call for Abstracts

Abstract Submission

Online abstract submission will open on 20 October 2019 and will close on 15 Feb 2020

Submission Timeline

The Scientific Committee will review all abstracts, and you will be notified whether your abstract has been accepted. The format of abstract presentation is a poster. All abstracts accepted will be published in the program book that will be distributed to all conference attendees.

Please note that your registration has to be received by 20 February 2020 for your abstracts to be published in the program book.

We will help print the poster, please provide it in our guidelines.


Poster Guidelines


  • A0 size – 841mm width x 1,189mm height (33.1 in × 46.8 in)

  • Strictly portrait orientation

  • Secretariat will advise on setup and tear down schedule closer to date                                                                                                                                           


Substitution/Withdrawal of Abstract Author


Due to program and publishing deadlines, withdrawal of abstract after 20 Feb 2020 is highly discouraged. Abstracts may be withdrawn during the submission period by emailing the Dialysis Access Synergy Congress Secretariat. There is no refund for registration fees if abstracts are withdrawn. Substitution/replacement of presenter is allowed with no penalty charge.

Structure of Abstract 

An abstract is welcome for any aspect relating to Dialysis Access for kidney disease patients. The content can be clinical study, translational research, audit, service review, case series and case report.


Abstracts must be submitted in English, not exceeding 350 words. Diagrams, photos and tables are encouraged. The material for presentation should be unpublished and original.


Should you need further information, please contact the Dialysis Access Synergy Secretariat.


A panel of judges formed by the organizing committee and faculty members will review all the posters presented. 3 prizes will be given to the top 3 posters with highest score in terms of scientific value, innovation and presentation.


The study team/author would need to provide a declaration of conflict of interest for himself/herself and all of their affiliations relating to the study of the submitted abstract. Such conflicts would include and without limitation to employment, grants/research support, expert testimony, consultancy, stock holding, honorarium, membership or other financial and/or materials support.

Ethics Guidelines

IRB approval is required for clinical trial involving human subjects. For translational research studies involving animal subjects, authors are to adhere to animal ethics guidelines. 

bottom of page